{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Certolizumab pegol plasma concentration was measured at Baseline in micrograms per millilitre (µg/mL).","groups":[{"description":"Matching placebo to certolizumab pegol (CZP) injections were administered every 2 weeks from Week 0 onwards. Subjects formed the Safety Set (SS).","id":"OG000","title":"Placebo (SS)"},{"description":"Certolizumab pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 6 onwards. Subjects formed the SS.","id":"OG001","title":"CZP 200 mg Q2W (SS)"}],"populationDescription":"The Safety Set (SS) consisted of all subjects who have received at least 1 dose of study medication. Note: None of the Safety Set subjects had Pharmacokinetic (PK) concentrations above the lower limit of quantification.","reportingStatus":"POSTED","timeFrame":"Baseline (Week 0)","title":"Certolizumab Pegol Plasma Concentration at Baseline","type":"PRIMARY"}